Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

Log in / Sign up

← Back to home

Suzhou Ugenex Therapeutics Co., Ltd.

Clinical trials sponsored by Suzhou Ugenex Therapeutics Co., Ltd., explained in plain language.

Upcoming readouts

Trials from this sponsor expected to report results within the next 12 months.

Gene therapy injection aims to slow vision loss in rare eye disease Results expected Mar 2027 (estimated)

Browse trials soon ready across all sponsors →

Not yet recruiting 1

Gene therapy injection aims to slow vision loss in rare eye disease

Disease control Not yet recruiting

This early-stage trial tests a single injection of a gene therapy drug called UGX202 in 6 adults with advanced retinitis pigmentosa, a genetic condition that causes vision loss. The main goal is to check if the treatment is safe and tolerable over 52 weeks. Researchers will also …

Early phase 1 • Sponsor: Suzhou UgeneX Therapeutics Co., Ltd. • Aim: Disease control

Last updated Jun 27, 2026 08:07 UTC